Theravance Biopharma (TBPH) Amortization of Deferred Charges (2021 - 2026)

Theravance Biopharma (TBPH) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 9.32% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 4.07% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 9.04% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for TBPH reached as high as $1.7 million in Q4 2022 and fell as low as $341000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $1.0 million across 5 years, with a median of $1.0 million in 2023.
• Across the five-year window, Amortization of Deferred Charges jumped 202.35% in 2023 and retreated 26.26% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.7 million in 2022, then fell by 16.25% to $1.4 million in 2023, then decreased by 26.26% to $1.1 million in 2024, then increased by 5.13% to $1.1 million in 2025, then retreated by 4.61% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.0 million in Q3 2025.